Journal article
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
RL Milne, A Osorio, T Ramón Y Cajal, M Baiget, A Lasa, E Diaz-Rubio, M De La Hoya, T Caldés, A Teulé, C Lázaro, I Blanco, J Balmaña, G Sánchez-Ollé, A Vega, A Blanco, I Chirivella, E Esteban Cardeñosa, M Durán, E Velasco, E Martínez De Dueñas Show all
Breast Cancer Research and Treatment | Published : 2010
Abstract
Environmental or lifestyle factors are likely to explain part of the heterogeneity in breast and ovarian cancer risk among BRCA1 and BRCA2 mutation carriers. We assessed parity as a risk modifier in 515 and 503 Spanish female carriers of mutations in BRCA1 and BRCA2, respectively. Hazard ratios (HR) and their corresponding 95% confidence intervals (CI) were estimated using weighted Cox proportional hazards regression, adjusted for year of birth and study centre. The results for ever being parous and number of live-births were very similar for carriers of mutations in both genes. For all mutation carriers combined, the estimated HR associated with ever having had a live-birth was 0.74 (95% co..
View full abstractGrants
Awarded by Fundación Mutua Madrileña
Funding Acknowledgements
We thank the patients and families without whose generous participation this study would not have been possible. We also thank Alicia Barroso and Fernando Fernandez who conducted the genetic testing at the Centro Nacional de Investigaciones Oncologicas; Guillermo Pita for information technology support; Marina Pollan and Fernando Artalejo from the Universidad Autonoma de Madrid; M. Carmen Alonso, Consol Lopez and David Fisas from the Hospital de la Santa Creu i Sant Pau; Daniel Fortuny, Neus Gadea, and Orland Diez from Hospital Vall d'Hebron; Vicenta Garces from the Hospital Clinico Universitario de Valencia, Pascual Bolufer from the Laboratorio de Biologia Molecular, Hospital La Fe de Valencia; Dolores Salas and Dolores Cuevas from the Grupo de Cancer Hereditario, Comunidad Valenciana. This work was partly supported by a grant from the Fondo de Investigacion Sanitario [PI081120]. TC, MdH and ED-R were supported by the RTICC (RD06/0020/0021), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and a grant from the Fundacion de Investigacion Medica Mutua Madrilena (FMMA/06). The work at the Instituto Catalan de Oncologia was supported by grants ISCIII-RETIC RD06/0020/1051 and 2005SGR00018. The Fundacion Publica Galega de Medicina Xenomica -SERGAS component of this work was partially supported by grants from the Ministerio de Sanidad y Consumo (PI052275) and the Xunta de Galicia (PGIDIT06BTF910101PR) to AV. AB has a fellowship from the Instituto de Salud Carlos III. The work at the Instituto de Biologia y Genetica Molecular was partly supported by the Hereditary Cancer Prevention Programme of the Regional Government of Castilla y Leon, and grant PI06/1102 (Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III). The work at the Hospital de Cruces was funded by the grant BIO07/CA/006.